FNArena Windows
Introduction to FNArena Windows
FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.
| ASX CODE | LAST PRICE | % MOVE | 52WK HIGH | 52WK LOW | P/E | CONSENSUS TARGET | UPSIDE/DOWNSIDE |
|---|---|---|---|---|---|---|---|
| CLV | $0.92 |
|
$1.17 | $0.53 |
|
||
| EBO | $17.41 |
|
$30.44 | $15.68 | 14.3 |
$23.81 |
|
| EXL | $0.01 | 0.00% | $0.02 | $0.01 |
|
||
| MCP | $0.13 | 0.00% | $0.28 | $0.12 |
|
||
| SIG | $2.69 |
|
$3.20 | $2.58 | 38.2 |
$3.163 |
|
| SK1 | $2.58 |
|
$2.96 | $2.13 | 23.5 |
$2.90 |
|
-6.12% 
36.8% Previous Stories
Sigma Farewells API, Heralds New Contract
Dec 17 2019
Sigma Healthcare has adjusted guidance to account for the renewed Chemist Warehouse contract, while Australian Pharmaceutical Industries finally takes its hat out of the merger ring.
Blackmores: Hopes Pinned On Restructuring
Nov 01 2019
Blackmores’ first half profit warning has sent analysts into a scramble to downgrade forecasts, but turnaround potential has been boosted by a shift in strategy.
Blackmores Peps Up Its Strategy For China
Apr 17 2019
Elevated inventory persisted over the March quarter amid falling sales for Blackmores, which has recognised the need to reposition its business to better cater for the Chinese market.
API/Sigma Merger Plan Rears, Again
Dec 17 2018
A merger of Australian Pharmaceutical Industries and Sigma Healthcare is logical but ACCC issues are uppermost in broker views.
Uncertainty Hinders Sigma Pharmaceuticals
Sep 11 2018
Uncertainty is likely to hinder Sigma Pharmaceuticals until a firm earnings base is established after the exit of its major customer.
Goodbye Chemist Warehouse, Hello Capital Return?
Jul 03 2018
Stockbrokers are still not keen on buying Sigma Healthcare shares, though a capital return might change their view.
Healthier Growth Required From Blackmores
Apr 27 2018
Several issues, mostly one-off, plagued Blackmores in the March quarter and some brokers query whether the growth profile justifies the elevated valuation.
Subdued Outlook For Aust Pharma Industries
Apr 26 2018
Soft retail conditions continue to cast a cloud over Australian Pharmaceutical Industries and brokers expect growth in FY18 will be a challenge.
Recovery For Blackmores?
Sep 05 2017
Michael Gable of Fairmont Equities suggests Blackmores may be building a base for a technical recovery.
Customer Dispute Overshadows Sigma
May 30 2017
Sigma Healthcare’s dispute with Chemist Warehouse had sounded warning bells for brokers.